Azusa Tanimoto
Overview
Explore the profile of Azusa Tanimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stewart C, Diao L, Xi Y, Wang R, Ramkumar K, Serrano A, et al.
Clin Cancer Res
. 2024 Aug;
30(20):4743-4754.
PMID: 39150543
Purpose: Large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine malignancy that, like small cell lung cancer (SCLC), is associated with the absence of druggable oncogenic drivers and dismal prognosis....
2.
Sakaguchi H, Tanimoto A, Sato S, Yanagimura N, Suzuki C, Takumi Y, et al.
Med Int (Lond)
. 2024 Jun;
1(4):8.
PMID: 38939364
The present study aimed to evaluate the clinical benefits of leucovorin, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) vs. gemcitabine plus Nab-paclitaxel (GnP) as a first-line therapy for patients with inoperable pancreatic...
3.
Heeke S, Gay C, Estecio M, Tran H, Morris B, Zhang B, et al.
Cancer Cell
. 2024 Jan;
42(2):225-237.e5.
PMID: 38278149
Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained challenging, particularly due to limited tissue availability. Given...
4.
Ramkumar K, Tanimoto A, Della Corte C, Stewart C, Wang Q, Shen L, et al.
Clin Cancer Res
. 2023 Jun;
29(16):3237-3249.
PMID: 37289191
Purpose: Therapeutic resistance to frontline therapy develops rapidly in small cell lung cancer (SCLC). Treatment options are also limited by the lack of targetable driver mutations. Therefore, there is an...
5.
Ohtsubo K, Miyake K, Arai S, Fukuda K, Suzuki C, Kotani H, et al.
Cancer Diagn Progn
. 2022 May;
2(3):378-383.
PMID: 35530650
Background/aim: We previously reported the usefulness of aberrant methylation of tumor suppressive miRNAs in bile to discriminate pancreaticobiliary cancers (PBCs) from benign pancreaticobiliary diseases (BD). Here we performed a methylation...
6.
Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, et al.
Thorac Cancer
. 2022 Apr;
13(10):1471-1478.
PMID: 35415873
Background: Dacomitinib is the second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC). EGFR-TKIs are often re-administered in Japan after the disease progression...
7.
Suzuki C, Nishiyama A, Arai S, Tange S, Tajima A, Tanimoto A, et al.
Cancer Sci
. 2022 Apr;
113(7):2323-2335.
PMID: 35363931
Tropomyosin receptor kinase (TRK) inhibitors have demonstrated histology-agnostic efficacy in patients with neurotrophic receptor tyrosine kinase (NTRK) gene fusion. Although responses to TRK inhibitors can be dramatic and durable, duration...
8.
Yanagimura N, Takeuchi S, Fukuda K, Arai S, Tanimoto A, Nishiyama A, et al.
NPJ Precis Oncol
. 2022 Mar;
6(1):11.
PMID: 35228642
Patients with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who are prescribed ALK-tyrosine kinase inhibitors (ALK-TKIs) rarely have complete responses, with residual tumors relapsing as heterogeneous resistant phenotypes....
9.
Yasuda H, Ichihara E, Sakakibara-Konishi J, Zenke Y, Takeuchi S, Morise M, et al.
Lung Cancer
. 2021 Nov;
162:140-146.
PMID: 34808485
Objectives: Several preclinical data proposed a potential efficacy of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for EGFR exon 20 insertion (EGFR ex20ins)-positive non-small cell lung cancer (NSCLC). However, reported...
10.
Nishiyama A, Hattori Y, Takeuchi S, Tanimoto A, Satouchi M, Murayama T, et al.
Intern Med
. 2021 Nov;
61(11):1735-1738.
PMID: 34803090
Immune checkpoint inhibitors (ICIs) have demonstrated marked efficacy in some cancer patients, but they may cause various severe immune-related adverse events. Alectinib is a second-generation anaplastic lymphoma kinase (ALK)-tyrosine kinase...